iptacopan Archives -

The final day of the ASH congress always includes a session on late-breaking studies, and this year was

ASH roundup: late breakers take the stage

https://pharmaphorum.com/news/ash-roundup-late-breakers-take-the-stage/

Novartis has a second positive phase 3 trial in the bag for its targeted factor B inhibitor iptacopan,

Novartis builds case for iptacopan as oral rival to PNH injectables

https://pharmaphorum.com/news/novartis-builds-case-for-iptacopan-as-oral-rival-to-pnh-injectables/

Novartis has chalked up another clinical trial win for its targeted factor B inhibitor iptacopan as it strives

Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial

https://pharmaphorum.com/news/novartis-oral-drug-iptacopan-tops-injectables-in-head-to-head-pnh-trial/

With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for

Revamped Novartis highlights top R&D programmes at management update

https://pharmaphorum.com/news/revamped-novartis-highlights-top-rd-programmes-at-management-update/

Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying

Novartis’ iptacopan hits the mark in rare kidney disease C3G

https://pharmaphorum.com/news/novartis-iptacopan-hits-the-mark-in-rare-kidney-disease-c3g/

The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris,

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

https://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/

iptacopan